Gynecologic Cancer

The Food and Drug Administration granted a full approval to Elahere for the treatment of certain patients with platinum-resistant gynecologic cancers.

My genetic testing covered 648 gene variants. Of course, researchers only know the significance of a fraction of those variants.

Keytruda plus chemotherapy has been granted a priority review by the FDA to treat certain patients with endometrial cancer.

“When you have support, you have answers to some of your unknowns and that can provide stability and ease in anxiety and depression, and truly propel you into thriving,” a cervical cancer survivor and advocate tells CURE®.

The Food and Drug Administration will speed up their review of Enhertu for previously treated patients with certain HER2-positive solid tumors.

The Food and Drug Administration (FDA) has recently approved Keytruda (pembrolizumab) plus chemoradiotherapy for the treatment of patients with stages 3 to 4A cervical cancer.

The FDA granted a Fast Track Designation to RC88, a novel antibody-drug conjugate, to treat patients with platinum-resistant gynecologic cancers.

Nearly 40% of patients who received treatment for cervical cancer were still being prescribed outpatient opioids for pain management six months later, according to recently published study findings.

The Food and Drug Administration approved Keytruda plus chemoradiotherapy for stage 3-4A cervical cancer.

The Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) intended to convert the accelerated approval granted to Tivdak (tisotumab vedotin-tftv) in 2021 to full approval for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

Next-generation sequencing was more successful in finding patients with endometrial and colorectal cancer with dMMR disease, indicating that they were eligible for immunotherapy.

A novel antibody drug conjugate was granted a Fast Track designation for certain patients with ovarian cancer.

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta.

A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.

A phase 3 trial demonstrated progression-free survival improvements with Tecentriq-chemotherapy combination in patients with endometrial carcinoma.

The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Platinum-based chemotherapy, when administered before chemoradiotherapy, improved progression-free and overall survival for patients with locally advanced cervical cancer.

Information about gynecologic cancers found on TikTok may not be credible or reliable, according to findings from a recent study.

The overexpression of the gene, BRD4, may be the cause of chemotherapy resistance in patients with high-grade serous ovarian cancer, according to research.

The FDA granted a priority review for a new supplemental Biologics License Application to Keytruda plus concurrent chemoradiotherapy for patients with locally advanced cervical cancer.

Rachelle’s unexpected departure reminded me I need to express my appreciation to these special, beloved providers now.

I always enjoyed writing about my summers, but this is what I would write today.

I faced cancer thrice and chose life each time — not because of some flowery will to live, but because I’m stubborn and wanted to prove that cancer is not the boss of me.

Here’s a look back at the therapies for solid cancers that gained FDA approval this summer.

Jemperli plus chemotherapy has been approved for the treatment of adults with primary advanced or recurrent mismatch repair deficient (dMMR) or microsatellite instability-high endometrial cancer.

High-level results from a phase 3 trial demonstrated that treatment with batiraxcept did not improve progression-free survival in patients with platinum-resistant ovarian cancer.

The Food and Drug Administration approved Jemperli with chemotherapy and then alone for patients with dMMR or MSI-H advanced endometrial cancer.

Patients with HER2-expressing cancers using Enhertu saw significant improvements in progression-free survival and overall survival.

We recently asked our audience of patients, survivors and caregivers about the ongoing cisplatin and carboplatin shortage. Here’s what they had to say.